Alterations in Faecal Metagenomics and Serum Metabolomics Indicate Management Strategies for Patients With Budd-Chiari Syndrome
We investigated the effects of gut microbiota and serum metabolite levels in patients with Budd-Chiari syndrome (B-CS) and their importance for guiding clinical management strategies. In total, 214 B-CS patients (93 untreated and 121 treated) and 41 healthy controls were enrolled. Gut microbiota and...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-10-01
|
| Series: | Frontiers in Cellular and Infection Microbiology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcimb.2021.730091/full |
| _version_ | 1819042655281086464 |
|---|---|
| author | Qinwei Lu Qinwei Lu Hao Xu Lin Zhou Lin Zhou Ruifang Zhang Zhen Li Peng Xu Tao Bai Zhiwei Wang Gang Wu Jianzhuang Ren Dechao Jiao Yan Song Rongtao Zhu Rongtao Zhu Jian Li Jian Li Weijie Wang Weijie Wang Ruopeng Liang Ruopeng Liang Lin Li Xiuxian Ma Xiuxian Ma Maoheng Zu Yuling Sun Yuling Sun |
| author_facet | Qinwei Lu Qinwei Lu Hao Xu Lin Zhou Lin Zhou Ruifang Zhang Zhen Li Peng Xu Tao Bai Zhiwei Wang Gang Wu Jianzhuang Ren Dechao Jiao Yan Song Rongtao Zhu Rongtao Zhu Jian Li Jian Li Weijie Wang Weijie Wang Ruopeng Liang Ruopeng Liang Lin Li Xiuxian Ma Xiuxian Ma Maoheng Zu Yuling Sun Yuling Sun |
| author_sort | Qinwei Lu |
| collection | DOAJ |
| description | We investigated the effects of gut microbiota and serum metabolite levels in patients with Budd-Chiari syndrome (B-CS) and their importance for guiding clinical management strategies. In total, 214 B-CS patients (93 untreated and 121 treated) and 41 healthy controls were enrolled. Gut microbiota and serum metabolome were analysed using shotgun metagenomics and liquid chromatography-mass spectrometry. The gut microbiota of the patients showed abundance of Campylobacter and low levels of Saccharomyces, Deinococcus, and Thiomonas (P < 0.05). Thirty metabolites, including taurocholate and (R)-3-hydroxybutyric acid, were identified in the patients (VIP > 1, P < 0.05 and FC > 1.2 or FC < 0.83). Random forest (RF) models showed that serum metabolome could effectively identify B-CS from healthy controls and RF-metabolomics exhibited perfect discrimination (AUC = 100%, 95% CI: 100% – 100%), which was significantly higher than that achieved by RF-metagenomics (AUC = 58.48%, 95% CI: 38.46% – 78.5%). Campylobacter concisus and taurocholate showed significant positive correlation in patients with clinical manifestations (P < 0.05). Actinobacteria levels were significantly higher in untreated patients than in treated patients (P < 0.05). Campylobacter and Veillonella levels were significantly higher in treated patients than in healthy controls (P < 0.05). We identified major alterations in the gut microbiota and serum metabolome of patients with B-CS. Faecal metagenomics- and serum metabolomics-guided management strategies are required for patients with B-CS. |
| first_indexed | 2024-12-21T09:44:20Z |
| format | Article |
| id | doaj.art-09c7a3a381844762ad3e4c07ef33726e |
| institution | Directory Open Access Journal |
| issn | 2235-2988 |
| language | English |
| last_indexed | 2024-12-21T09:44:20Z |
| publishDate | 2021-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cellular and Infection Microbiology |
| spelling | doaj.art-09c7a3a381844762ad3e4c07ef33726e2022-12-21T19:08:22ZengFrontiers Media S.A.Frontiers in Cellular and Infection Microbiology2235-29882021-10-011110.3389/fcimb.2021.730091730091Alterations in Faecal Metagenomics and Serum Metabolomics Indicate Management Strategies for Patients With Budd-Chiari SyndromeQinwei Lu0Qinwei Lu1Hao Xu2Lin Zhou3Lin Zhou4Ruifang Zhang5Zhen Li6Peng Xu7Tao Bai8Zhiwei Wang9Gang Wu10Jianzhuang Ren11Dechao Jiao12Yan Song13Rongtao Zhu14Rongtao Zhu15Jian Li16Jian Li17Weijie Wang18Weijie Wang19Ruopeng Liang20Ruopeng Liang21Lin Li22Xiuxian Ma23Xiuxian Ma24Maoheng Zu25Yuling Sun26Yuling Sun27Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaInstitute of Hepatobiliary and Pancreatic Diseases, Zhengzhou University, Zhengzhou, ChinaDepartment of Interventional Radiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, ChinaInstitute of Hepatobiliary and Pancreatic Diseases, Zhengzhou University, Zhengzhou, ChinaDepartment of Digestive, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Ultrasound Diagnosis, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Endovascular Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Vascular Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Vascular Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Vascular Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Vascular Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaInstitute of Hepatobiliary and Pancreatic Diseases, Zhengzhou University, Zhengzhou, ChinaDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaInstitute of Hepatobiliary and Pancreatic Diseases, Zhengzhou University, Zhengzhou, ChinaDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaInstitute of Hepatobiliary and Pancreatic Diseases, Zhengzhou University, Zhengzhou, ChinaDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaInstitute of Hepatobiliary and Pancreatic Diseases, Zhengzhou University, Zhengzhou, ChinaDepartment of Interventional Radiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, ChinaDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaInstitute of Hepatobiliary and Pancreatic Diseases, Zhengzhou University, Zhengzhou, ChinaDepartment of Interventional Radiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, ChinaDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaInstitute of Hepatobiliary and Pancreatic Diseases, Zhengzhou University, Zhengzhou, ChinaWe investigated the effects of gut microbiota and serum metabolite levels in patients with Budd-Chiari syndrome (B-CS) and their importance for guiding clinical management strategies. In total, 214 B-CS patients (93 untreated and 121 treated) and 41 healthy controls were enrolled. Gut microbiota and serum metabolome were analysed using shotgun metagenomics and liquid chromatography-mass spectrometry. The gut microbiota of the patients showed abundance of Campylobacter and low levels of Saccharomyces, Deinococcus, and Thiomonas (P < 0.05). Thirty metabolites, including taurocholate and (R)-3-hydroxybutyric acid, were identified in the patients (VIP > 1, P < 0.05 and FC > 1.2 or FC < 0.83). Random forest (RF) models showed that serum metabolome could effectively identify B-CS from healthy controls and RF-metabolomics exhibited perfect discrimination (AUC = 100%, 95% CI: 100% – 100%), which was significantly higher than that achieved by RF-metagenomics (AUC = 58.48%, 95% CI: 38.46% – 78.5%). Campylobacter concisus and taurocholate showed significant positive correlation in patients with clinical manifestations (P < 0.05). Actinobacteria levels were significantly higher in untreated patients than in treated patients (P < 0.05). Campylobacter and Veillonella levels were significantly higher in treated patients than in healthy controls (P < 0.05). We identified major alterations in the gut microbiota and serum metabolome of patients with B-CS. Faecal metagenomics- and serum metabolomics-guided management strategies are required for patients with B-CS.https://www.frontiersin.org/articles/10.3389/fcimb.2021.730091/fullBudd-Chiari syndromegut microbiotametagenomicsmetabolomicsmanagement strategies |
| spellingShingle | Qinwei Lu Qinwei Lu Hao Xu Lin Zhou Lin Zhou Ruifang Zhang Zhen Li Peng Xu Tao Bai Zhiwei Wang Gang Wu Jianzhuang Ren Dechao Jiao Yan Song Rongtao Zhu Rongtao Zhu Jian Li Jian Li Weijie Wang Weijie Wang Ruopeng Liang Ruopeng Liang Lin Li Xiuxian Ma Xiuxian Ma Maoheng Zu Yuling Sun Yuling Sun Alterations in Faecal Metagenomics and Serum Metabolomics Indicate Management Strategies for Patients With Budd-Chiari Syndrome Frontiers in Cellular and Infection Microbiology Budd-Chiari syndrome gut microbiota metagenomics metabolomics management strategies |
| title | Alterations in Faecal Metagenomics and Serum Metabolomics Indicate Management Strategies for Patients With Budd-Chiari Syndrome |
| title_full | Alterations in Faecal Metagenomics and Serum Metabolomics Indicate Management Strategies for Patients With Budd-Chiari Syndrome |
| title_fullStr | Alterations in Faecal Metagenomics and Serum Metabolomics Indicate Management Strategies for Patients With Budd-Chiari Syndrome |
| title_full_unstemmed | Alterations in Faecal Metagenomics and Serum Metabolomics Indicate Management Strategies for Patients With Budd-Chiari Syndrome |
| title_short | Alterations in Faecal Metagenomics and Serum Metabolomics Indicate Management Strategies for Patients With Budd-Chiari Syndrome |
| title_sort | alterations in faecal metagenomics and serum metabolomics indicate management strategies for patients with budd chiari syndrome |
| topic | Budd-Chiari syndrome gut microbiota metagenomics metabolomics management strategies |
| url | https://www.frontiersin.org/articles/10.3389/fcimb.2021.730091/full |
| work_keys_str_mv | AT qinweilu alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome AT qinweilu alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome AT haoxu alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome AT linzhou alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome AT linzhou alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome AT ruifangzhang alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome AT zhenli alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome AT pengxu alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome AT taobai alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome AT zhiweiwang alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome AT gangwu alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome AT jianzhuangren alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome AT dechaojiao alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome AT yansong alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome AT rongtaozhu alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome AT rongtaozhu alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome AT jianli alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome AT jianli alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome AT weijiewang alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome AT weijiewang alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome AT ruopengliang alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome AT ruopengliang alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome AT linli alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome AT xiuxianma alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome AT xiuxianma alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome AT maohengzu alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome AT yulingsun alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome AT yulingsun alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome |